S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
AI Stock Caught Trading Under Secret Name (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
AI Stock Caught Trading Under Secret Name (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
AI Stock Caught Trading Under Secret Name (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
AI Stock Caught Trading Under Secret Name (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
AI Stock Caught Trading Under Secret Name (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
AI Stock Caught Trading Under Secret Name (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
AI Stock Caught Trading Under Secret Name (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
AI Stock Caught Trading Under Secret Name (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
NASDAQ:SABS

SAB Biotherapeutics (SABS) Stock Forecast, Price & News

$0.67
+0.01 (+1.52%)
(As of 10/3/2023 ET)
Compare
Today's Range
$0.63
$0.70
50-Day Range
$0.47
$0.85
52-Week Range
$0.37
$1.45
Volume
90,836 shs
Average Volume
486,379 shs
Market Capitalization
$35.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

SAB Biotherapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
198.5% Upside
$2.00 Price Target
Short Interest
Healthy
0.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.05mentions of SAB Biotherapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.49) to ($0.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

202nd out of 966 stocks

Biological Products, Except Diagnostic Industry

25th out of 150 stocks


SABS stock logo

About SAB Biotherapeutics (NASDAQ:SABS) Stock

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.

SABS Price History

SABS Stock News Headlines

Something is Coming for America's Top Stock
This stock has already doubled this year - but it could hurt your portfolio if you hold it much longer. Learn why here.
SAB Biotherapeutics GAAP EPS of -$0.14
SAB Biotherapeutics (SABS) Gets a Buy from Chardan Capital
Analyst Ratings for SAB Biotherapeutics
Something is Coming for America's Top Stock
This stock has already doubled this year - but it could hurt your portfolio if you hold it much longer. Learn why here.
SAB Biotherapeutics (SABS) Receives a Buy from H.C. Wainwright
H.C. Wainwright Remains a Buy on SAB Biotherapeutics (SABS)
SAB Biotherapeutics Inc.
8-K: SAB Biotherapeutics, Inc.
See More Headlines
Receive SABS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

SABS Company Calendar

Last Earnings
8/21/2023
Today
10/04/2023
Next Earnings (Estimated)
11/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SABS
Fax
N/A
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.00
High Stock Price Forecast
$2.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+198.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-18,740,000.00
Net Margins
-454.82%
Pretax Margin
-454.42%

Debt

Sales & Book Value

Annual Sales
$23.90 million
Book Value
$0.72 per share

Miscellaneous

Free Float
35,629,000
Market Cap
$35.05 million
Optionable
Not Optionable
Beta
1.34
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Samuel J. Reich (Age 48)
    Exec. Chairman
    Comp: $376.2k
  • Dr. Eddie Joe Sullivan Ph.D. (Age 57)
    Co-Founder, Pres, CEO & Director
    Comp: $430.62k
  • Ms. Christine E. Hamilton M.B.A. (Age 67)
    Co-Founder & Independent Director
    Comp: $25k
  • Dr. Alexandra Kropotova M.B.A. (Age 50)
    M.D., Exec. VP & Chief Medical Officer
    Comp: $486.96k
  • Dr. Edward D. Hamilton D.V.M.
    Co-Founder & Board Observer
  • Mr. Russell P. Beyer C.M.A. (Age 68)
    M.B.A., Exec. VP & CFO
  • Dr. Christoph Bausch M.B.A. (Age 52)
    Ph.D., Exec. VP & COO
  • Dr. Carlos N. Carillo Ph.D.
    Sr. VP of Regulatory Affairs













SABS Stock - Frequently Asked Questions

Should I buy or sell SAB Biotherapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SAB Biotherapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SABS shares.
View SABS analyst ratings
or view top-rated stocks.

What is SAB Biotherapeutics' stock price forecast for 2023?

1 analysts have issued twelve-month price objectives for SAB Biotherapeutics' shares. Their SABS share price forecasts range from $2.00 to $2.00. On average, they expect the company's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 198.5% from the stock's current price.
View analysts price targets for SABS
or view top-rated stocks among Wall Street analysts.

How have SABS shares performed in 2023?

SAB Biotherapeutics' stock was trading at $0.5899 at the beginning of the year. Since then, SABS shares have increased by 13.6% and is now trading at $0.67.
View the best growth stocks for 2023 here
.

Are investors shorting SAB Biotherapeutics?

SAB Biotherapeutics saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 306,500 shares, a decrease of 17.5% from the August 31st total of 371,600 shares. Based on an average daily volume of 35,900 shares, the short-interest ratio is presently 8.5 days. Approximately 0.8% of the shares of the company are short sold.
View SAB Biotherapeutics' Short Interest
.

When is SAB Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023.
View our SABS earnings forecast
.

How were SAB Biotherapeutics' earnings last quarter?

SAB Biotherapeutics, Inc. (NASDAQ:SABS) posted its earnings results on Monday, August, 21st. The company reported ($0.14) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.14). The firm earned $0.09 million during the quarter. SAB Biotherapeutics had a negative trailing twelve-month return on equity of 110.34% and a negative net margin of 454.82%.

What is SAB Biotherapeutics' stock symbol?

SAB Biotherapeutics trades on the NASDAQ under the ticker symbol "SABS."

How do I buy shares of SAB Biotherapeutics?

Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SAB Biotherapeutics' stock price today?

One share of SABS stock can currently be purchased for approximately $0.67.

How much money does SAB Biotherapeutics make?

SAB Biotherapeutics (NASDAQ:SABS) has a market capitalization of $35.05 million and generates $23.90 million in revenue each year.

How can I contact SAB Biotherapeutics?

SAB Biotherapeutics' mailing address is 300 W. 41ST STREET SUITE 202, MIAMI BEACH FL, 33140. The official website for the company is www.bigcypressaccorp.com. The company can be reached via phone at 605-679-6980 or via email at ir@bigcypressaccorp.com.

This page (NASDAQ:SABS) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -